A Study LY2228820 for Recurrent Ovarian Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 25, 2017

Study Completion Date

May 11, 2018

Conditions
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Interventions
DRUG

LY2228820

Administered Orally

DRUG

Carboplatin

Administered IV

DRUG

Placebo

Administered Orally

DRUG

Gemcitabine

Administered IV

Trial Locations (30)

3000

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven

3053

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parkville

4120

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenslopes

5000

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Adelaide

6009

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands

10117

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin

17489

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greifswald

19107

Thomas Jefferson University, Philadelphia

21237

Franklin Square Hospital Center, Baltimore

33612

H Lee Moffitt Cancer Center, Tampa

34239

Sarasota Memorial Hospital, Sarasota

37203

SMO Sarah Cannon Research Inst., Nashville

45122

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Essen

45136

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Essen

55131

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz

63110

Barnes Jewish Hospital, St Louis

73104

University of Oklahoma Health Sciences Center, Oklahoma City

75246

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas

75702

Tyler Cancer Center, Tyler

76022

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Bedford

76104

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Fort Worth

77380

Texas Oncology - The Woodlands, The Woodlands

US Oncology, The Woodlands

78229

Cancer Care Centers of South Texas, San Antonio

78731

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Austin

81675

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., München

85013

St Josephs Hospital and Medical Center, Phoenix

85710

Arizona Oncology Associates, P.C., Tucson

98684

Northwest Cancer Specialists PC, Vancouver

08901

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT01663857 - A Study LY2228820 for Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter